Patients Above Profits
Civica Rx has its eye on ANDAs
Stephanie Sutton |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques.
Civica Rx raised a few eyebrows in 2018, when it was founded as a not-for-profit to manufacture important generic medicines for the US market. But, since then, the company has gone from strength to strength – 18 medicines are now in production or shipped for use in hospitals across the USA.
A recent announcement from the company draws attention to the signing of a long-term (seven-year) agreement with Thermo Fisher Scientific, which will drive the development of Civica-owned Abbreviated New Drug Applications (ANDAs). Initially, the collaboration will focus on nine critical medications that have been in short supply or where the drug supply chain is considered fragile because there are too few manufacturers making the drugs.
The company also notes its interest in talking to generic drug manufacturers who are considering retiring or withdrawing their ANDA for essential medicines that are at risk of being in short supply.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine